Tuesday, May 26, 2015 9:01:30 AM
Company Finalizing Plans to Commence Clinical Trial for COTI-2 in the Second Half of 2015
http://www.marketwired.com/press-release/-2023097.htm
LONDON, ON--(Marketwired - May 26, 2015) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE: COT) (OTCQB: COTQF), announced today that the U.S. Food and Drug Administration ("FDA") granted investigational new drug status ("IND") for COTI-2, the Company's small molecule activator of misfolded mutant p53 protein, in gynecological cancers.
"The grant of this IND marks the achievement of the second important milestone for COTI-2 in 2015 and builds on the Orphan Drug designation received for ovarian cancer from the FDA in June 2014," said Dr. Wayne Danter, President and CEO. "During preclinical studies, COTI-2 with its novel mechanism of action demonstrated selective and potent anti-cancer p53-dependent activity in many cancers. We look forward to reproducing these encouraging results in a clinical setting and confirming that COTI-2 is a highly promising novel treatment option for women with gynecological cancers having p53 mutations."
The Company plans to commence a Phase 1 clinical trial in the second half of calendar 2015 in partnership with the University of Texas, MD Anderson Cancer Center in Houston.
The grant of this IND triggers the issuance of 715,720 common shares of the Company as final payment of contingent share consideration that arose on the acquisition of DDP Therapeutics in November 2007.
About COTI-2
COTI-2 is a small molecule activator of misfolded mutant p53 protein approved for clinical development. Extensive studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in many common p53 mutations. Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in a wide range of cancers, including ovarian, lung, colorectal, breast, liver, bladder and other cancers. COTI-2's specific protein target, low toxicity, combination effectiveness with standard agents, and potential for longer term outpatient therapy as an oral agent, supports a dramatic change in the treatment of susceptible cancers.
$COTQF $COT.V
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM